# Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

> **NCT03407976** · PHASE1 · TERMINATED · sponsor: **University of Utah** · enrollment: 5 (actual)

## Conditions studied

- Advanced Malignancies
- Urothelial Carcinoma
- MSI-H or dMMR Solid Tumors
- Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03407976
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-19
- **Primary completion:** 2019-08-19
- **Final completion:** 2020-07-02
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Funding source withdrew financial support prior to start of Phase II portion of study
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03407976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03407976, "Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03407976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*